<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3625">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04830735</url>
  </required_header>
  <id_info>
    <org_study_id>0S-20-5</org_study_id>
    <secondary_id>NCI-2020-04367</secondary_id>
    <secondary_id>0S-20-5</secondary_id>
    <secondary_id>P30CA014089</secondary_id>
    <nct_id>NCT04830735</nct_id>
  </id_info>
  <brief_title>Dasatinib for the Treatment of Moderate and Severe COVID-19</brief_title>
  <official_title>A Phase II Randomized Double-Blind Trial of Dasatinib Modulation of Hyperinflammation in Moderate and Severe Patients With COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Southern California</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial investigates how well dasatinib works in treating patients with moderate&#xD;
      and severe COVID-19. Dasatinib is a drug used to treat chronic leukemia which may help reduce&#xD;
      the strong inflammation caused by COVID-19 that can damage the lungs or other organs.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the proportion of patients requiring intubation/ventilator support, requiring&#xD;
      rescue with tocilizumab, or dying.&#xD;
&#xD;
      II. To determine 1 month survival.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To estimate the safety and tolerability of dasatinib anhydrous (dasatinib) in the setting&#xD;
      of COVID-19 infection.&#xD;
&#xD;
      II. To determine change in C-reactive protein (CRP) levels after starting therapy.&#xD;
&#xD;
      III. To document activity of dasatinib in lessening cytokine release syndrome (CRS) and&#xD;
      sequential organ failure assessment (SOFA) score.&#xD;
&#xD;
      EXPLORATORY OBJECTIVES:&#xD;
&#xD;
      I. Interleukin-6 /cytokine assay weekly on treatment protocol. II. Ferritin levels at study&#xD;
      entry and every (q) 2 days on treatment protocol. III. D-dimer levels at study entry and q 2&#xD;
      days on treatment protocol.&#xD;
&#xD;
      OUTLINE: Patients are randomized to 1 of 2 arms.&#xD;
&#xD;
      ARM I: Patients receive dasatinib anhydrous orally (PO) once daily (QD) for 14 days in the&#xD;
      absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      ARM II: Patients receive placebo PO QD for 14 days in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up for 28 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 15, 2021</start_date>
  <completion_date type="Anticipated">April 15, 2024</completion_date>
  <primary_completion_date type="Anticipated">April 15, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of participants requiring invasive mechanical ventilation, requiring tocilizumab or dying</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>Outcome reported as the number of patients requiring mechanical ventilation, requiring tocilizumab or dying.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute lymphocyte count</measure>
    <time_frame>Baseline, during treatment (day 1-14) up to 1 month</time_frame>
    <description>Assessment via standard blood chemistry and metabolic panel</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CRP (C-reactive protein) level</measure>
    <time_frame>Baseline, during treatment (day 1-14) up to 1 month</time_frame>
    <description>Assessment via standard blood chemistry and metabolic panel</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of the SOFA (Sequential Organ Failure Assessment)</measure>
    <time_frame>Baseline, during treatment (day 1-14) up to 1 month</time_frame>
    <description>The SOFA score assessment will be based on PaO2/FiO2, platelets, Glasgow coma scale (GCS), bilirubin, Mean arterial pressure OR administration of vasoactive agents required, and Serum creatinine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related side effects</measure>
    <time_frame>During treatment and up to 30 days after the last treatment dose</time_frame>
    <description>Outcome reported as the number of adverse events and serious adverse events that occurred.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiological response</measure>
    <time_frame>Baseline (optional), after seven days and if clinically indicated(up to 1 month)</time_frame>
    <description>Will be evaluated by chest x-ray or pulmonary computed tomography (CT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospitalization</measure>
    <time_frame>From baseline up to patient's discharge (up to 1 month)</time_frame>
    <description>Outcome reported as the duration of hospitalization of patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Remission of respiratory symptoms</measure>
    <time_frame>Up to 1 month</time_frame>
    <description>Time to invasive mechanical ventilation (if not previously initiated) calculated from baseline to intubation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Remission of respiratory symptoms</measure>
    <time_frame>Up to 1 month</time_frame>
    <description>Time to definitive extubation calculated from intubation (any time occurred) to extubation in days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Remission of respiratory symptoms</measure>
    <time_frame>Up to 1 month</time_frame>
    <description>Time to independence from oxygen therapy in days.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Symptomatic COVID-19 Infection Laboratory-Confirmed</condition>
  <arm_group>
    <arm_group_label>Arm I (dasatinib anhydrous)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive dasatinib anhydrous PO QD for 14 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (placebo administration)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive placebo PO QD for 14 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dasatinib Anhydrous</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm I (dasatinib anhydrous)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Administration</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm II (placebo administration)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have laboratory test proven COVID19 and symptomatic disease requiring&#xD;
             hospitalization: virological diagnosis of Sars-CoV2 infection (polymerase chain&#xD;
             reaction [PCR]) within 14 days&#xD;
&#xD;
          -  Able to sign informed consent for participation in the study&#xD;
&#xD;
          -  Subject is hospitalized with one or more of the following:&#xD;
&#xD;
               -  Moderate disease: peripheral capillary oxygen saturation (SpO2) &gt;= 93% on room&#xD;
                  air with one of the following risk factors for developing severe disease: age &gt;=&#xD;
                  60 years, history of hypertension, diabetes mellitus, cardiac disease, chronic&#xD;
                  lung disease, obesity (calculated body mass index [BMI] &gt;= 30 kg/m^2), and&#xD;
                  cardiovascular disease, clinical and/or radiological evidence of chest&#xD;
                  involvement, CRP &gt; 2X upper limit of normal, doubling of CRP in 24 hours where&#xD;
                  chest findings and CRP elevation not explained by other underlying disease.&#xD;
&#xD;
        After the first interim analysis, we may allow enrollment of severe disease COVID infected&#xD;
        patients if safety and efficacy analysis appears favorable:&#xD;
&#xD;
          -  Severe disease:&#xD;
&#xD;
               -  Respiratory rate &gt;= 30 breaths/ minute (min)&#xD;
&#xD;
               -  SpO2 &lt; 93% while breathing room air&#xD;
&#xD;
               -  Partial pressure of oxygen measurement (PaO2)/fraction of inspired oxygen (FiO2)&#xD;
                  =&lt; 300 mmHg&#xD;
&#xD;
                    -  Absolute neutrophil count (ANC) &gt; 1000 (baseline blood counts)&#xD;
&#xD;
                    -  Platelets &gt; 50,000 / mmc (baseline blood counts)&#xD;
&#xD;
                    -  Alanine aminotransferase/aspartate aminotransferase (ALT/AST) &lt; 5 times the&#xD;
                       upper limit of the normality&#xD;
&#xD;
                    -  Total bilirubin &lt; 3 x institutional upper limit of normal (IULN)&#xD;
&#xD;
                    -  Creatinine &lt; 2.5 times the upper limit of the normality&#xD;
&#xD;
                    -  Azithromycin allowed but if on both drugs patient should be on constant&#xD;
                       cardiovascular (CV) monitoring&#xD;
&#xD;
                    -  Subject must understand and voluntarily sign an informed consent form (ICF)&#xD;
                       prior to any study-related assessment/procedures being conducted&#xD;
&#xD;
                    -  Subject is willing and able to adhere to the study visit schedule and other&#xD;
                       protocol requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pleural effusion &gt; grade 2 evident on chest x-ray (CXR) or chest computed tomography&#xD;
             (CT)&#xD;
&#xD;
          -  Intubation/mechanical ventilation&#xD;
&#xD;
          -  Known hypersensitivity to dasatinib&#xD;
&#xD;
          -  Patient being treated with immunomodulators or anti-rejection drugs&#xD;
&#xD;
          -  Known active infections or other clinical condition that contraindicate dasatinib and&#xD;
             cannot be treated or solved according to the judgement of the clinician&#xD;
&#xD;
          -  ALT/AST &gt; 5 times the upper limit of the normality&#xD;
&#xD;
          -  Total bilirubin &gt; 3 x IULN&#xD;
&#xD;
          -  Neutrophils &lt; 1000 / mmc unless; platelets &lt; 50,000 / mmc&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ann Mohrbacher, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Southern California</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christine Duran</last_name>
    <phone>323-865-0371</phone>
    <email>Duran_C@med.usc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>USC / Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Ann Mohrbacher</last_name>
      <phone>323-865-3924</phone>
      <email>mohrbach@med.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Ann Mohrbacher</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 1, 2021</study_first_submitted>
  <study_first_submitted_qc>April 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2021</study_first_posted>
  <last_update_submitted>April 1, 2021</last_update_submitted>
  <last_update_submitted_qc>April 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Laboratory Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dasatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

